公开(公告)号：US20210002323A1

公开(公告)日：2021-01-07

申请号：US16978208

申请日：2019-03-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Brian E. FINK ,  Zheming Ruan

IPC: C07H21/02 ,  C07K16/28

Abstract: The present invention is directed to compounds of formulae (I) and (II) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US20210253624A1

公开(公告)日：2021-08-19

申请号：US16849091

申请日：2018-10-16

Applicant: Bristol-Myers Squibb Company

Inventor： Brian E. FINK ,  Yufen Zhao ,  Libing Chen ,  Audris Huang

IPC: C07H21/02 ,  C07K16/28 ,  A61K45/06

Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US20220117995A1

公开(公告)日：2022-04-21

申请号：US16754301

申请日：2018-10-09

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Brian E. FINK ,  Dharmpal S. Dodd ,  Yufen Zhao ,  Lan-Ying Qin ,  Zheming Ruan ,  Lalgudi S. Harikrishnan ,  Muthoni G. Kamau

IPC: A61K31/7084 ,  A61K39/395 ,  C07H21/04

Abstract: The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US20190030057A1

公开(公告)日：2019-01-31

申请号：US16047071

申请日：2018-07-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Brian E. FINK ,  Dharmpal S. Dodd ,  Lan-ying Qin ,  Zheming Ruan ,  Yufen Zhao ,  Lalgudi S. Harikrishnan ,  Muthoni G. Kamau

IPC: A61K31/7084 ,  C07H21/04 ,  A61K45/06

Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US20200079815A1

公开(公告)日：2020-03-12

申请号：US16683667

申请日：2019-11-14

Applicant: Bristol-Myers Squibb Company

Inventor： Brian E. FINK ,  Dharmpal S. Dodd ,  Steven J. Walker ,  Libing Chen ,  Yufen Zhao ,  Zheming Ruan ,  Lan-Ying Qin ,  Peter Kinam Park ,  Muthoni G, Kamau ,  Lalgudi S. Harikrishnan

IPC: C07H19/213 ,  A61P35/00 ,  C07H21/02 ,  C07H21/00

Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US20180215761A1

公开(公告)日：2018-08-02

申请号：US15746597

申请日：2016-07-21

Applicant: Bristol-Myers Squibb Company

Inventor： Lalgudi S. HARIKRISHNAN ,  Brian E. FINK ,  Robert M. BORZILLERI ,  Gopikishan TONUKUNURU ,  Hasibur RAHAMAN ,  Jayakumar SANKARA WARRIER ,  Balaji SESHADRI

IPC: C07D487/04 ,  A61K31/541 ,  A61K31/53

CPC classification number: C07D487/04 ,  A61K31/53 ,  A61K31/541

Abstract: The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβ R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.